ATE496893T1 - Isochinolinonderivate und deren verwendung als medikamente - Google Patents

Isochinolinonderivate und deren verwendung als medikamente

Info

Publication number
ATE496893T1
ATE496893T1 AT03814127T AT03814127T ATE496893T1 AT E496893 T1 ATE496893 T1 AT E496893T1 AT 03814127 T AT03814127 T AT 03814127T AT 03814127 T AT03814127 T AT 03814127T AT E496893 T1 ATE496893 T1 AT E496893T1
Authority
AT
Austria
Prior art keywords
sup
medications
isoquinolinone derivatives
compounds
disclosed
Prior art date
Application number
AT03814127T
Other languages
English (en)
Inventor
Alan Johnson
Satoru Kaneko
Raju Mohan
Kozo Oda
Edwin Schweiger
Original Assignee
X Ceptor Therapeutics Inc
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Ceptor Therapeutics Inc, Sankyo Co filed Critical X Ceptor Therapeutics Inc
Application granted granted Critical
Publication of ATE496893T1 publication Critical patent/ATE496893T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03814127T 2002-12-20 2003-12-17 Isochinolinonderivate und deren verwendung als medikamente ATE496893T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43585102P 2002-12-20 2002-12-20
PCT/US2003/040275 WO2004058717A1 (en) 2002-12-20 2003-12-17 Isoquinolinone derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE496893T1 true ATE496893T1 (de) 2011-02-15

Family

ID=32682285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814127T ATE496893T1 (de) 2002-12-20 2003-12-17 Isochinolinonderivate und deren verwendung als medikamente

Country Status (8)

Country Link
US (2) US7265131B2 (de)
EP (1) EP1572660B1 (de)
AT (1) ATE496893T1 (de)
AU (1) AU2003301020A1 (de)
DE (1) DE60335911D1 (de)
ES (1) ES2361924T3 (de)
TW (1) TW200418801A (de)
WO (1) WO2004058717A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US8168666B2 (en) 2006-11-30 2012-05-01 Kowa Company, Ltd. Substituted carbinol compound
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
KR101638035B1 (ko) 2007-01-22 2016-07-11 지티엑스, 인코포레이티드 핵 수용체에 결합하는 물질
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
CL2008001903A1 (es) * 2007-06-29 2009-03-06 Harvard College Linea celular que comprende una o mas celulas que expresan en forma estable una secuencia de acidos nucleicos que codifica un promotor regulador de esteroles y que esta unida en forma operativa a una secuencia de acidos nucleicos que codifica una etiqueta detectable; y metodo para determinar si un compuesto reduce el colesterol.
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US7919509B2 (en) 2008-02-29 2011-04-05 Kowa Company, Ltd. 2-oxochromene derivatives
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
US8008306B2 (en) 2008-04-30 2011-08-30 Kowa Company, Ltd. Quinoline compounds
US20110237600A1 (en) * 2008-05-12 2011-09-29 Amnestix, Inc. Compounds for improving learning and memory
WO2009144961A1 (ja) 2008-05-29 2009-12-03 興和株式会社 環状リンカーを有する置換カルビノール化合物
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
ES2542835T3 (es) * 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
EP2408300B1 (de) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CN102438991B (zh) 2009-04-29 2015-08-26 兴和株式会社 具有杂环连接基的甲醇化合物
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ, インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (de) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Festen formen von isochinolinonen
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
SG11201405378VA (en) 2012-03-02 2014-09-26 Anayaderm Inc Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN102875466A (zh) * 2012-04-23 2013-01-16 中国药科大学 异喹啉酮衍生物,其制备方法及其医药用途
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20160048997A (ko) 2013-09-04 2016-05-04 알렉사르 테라퓨틱스 인코퍼레이티드 간 x 수용체 (lxr) 조절인자
EP3041835B1 (de) 2013-09-04 2020-04-08 Ellora Therapeutics, Inc. Modulatoren des leber-x-rezeptors (lxr)
CA2922469A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (de) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und verwendungen davon
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (de) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Kombinationstherapie
EP3713575A4 (de) 2017-11-21 2021-08-25 Rgenix, Inc. Polymorphe und ihre verwendung
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3830259A4 (de) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. Auf muskel abzielende komplexe und ihre verwendungen zur behandlung von fazioskapulohumeraler muskeldystrophie
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ,インコーポレーテッド 金属塩及びその使用
EP4097083A1 (de) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitoren von apol1 und verfahren zur verwendung davon
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
EP4178955A1 (de) 2020-07-11 2023-05-17 Pfizer Inc. Antivirale heteroarylketonderivate
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
CN116693456A (zh) * 2022-02-28 2023-09-05 复旦大学 异喹啉酮类化合物及其制备方法和应用
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
CN117486753B (zh) * 2023-10-13 2026-04-03 天津科技大学 一类具有驱蚊作用的含氟苯甲酰二乙胺类化合物、方法及在驱蚊剂中的应用
CN118440034A (zh) * 2024-04-17 2024-08-06 南京合创药业有限公司 一种合成3-溴呋喃的新方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452027A (en) * 1967-07-03 1969-06-24 American Home Prod 2-hydroxyalkylisocarbostyrils
JPS5424882A (en) * 1977-07-22 1979-02-24 Yamanouchi Pharmaceut Co Ltd Novel heterocyclic compounds and their preparation
US5115626A (en) * 1988-09-30 1992-05-26 Rapak, Inc. Apparatus for filling flexible plastic bags carried in a continuous web and supplies therefore
US4969310A (en) * 1989-05-12 1990-11-13 Automated Packaging Systems, Inc. Packaging machine and method
CA2028538A1 (en) * 1989-10-27 1991-04-28 Hideaki Natsugari 4-substituted isoquinolone derivatives, their production and use
US5187917A (en) * 1990-10-29 1993-02-23 Cvp Systems, Inc. Automatic packaging apparatus and method and flexible pouch therefor
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
ATE162525T1 (de) 1991-07-30 1998-02-15 Ciba Geigy Ag Heteroaryl substituierte hydroxylaminderivate als lipoxygenase-inhibitoren
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
JP3141051B2 (ja) * 1992-10-09 2001-03-05 日清製粉株式会社 抗動脈硬化剤
SE501545C2 (sv) * 1993-05-05 1995-03-13 Jan Jostler Bana för förpackningsämnen samt sätt att öppna och fylla förpackningsfickor i banan
US5607898A (en) * 1993-08-02 1997-03-04 Idemitsu Kosan Company, Ltd. Pyrazole derivatives
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
US5642599A (en) * 1994-11-14 1997-07-01 Tisma Machinery Corporation Automatic packaging machine for boxes with paper end liners
FR2728900B1 (fr) * 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
WO1996037493A1 (de) * 1995-05-26 1996-11-28 Bayer Aktiengesellschaft Pyridyl-thiazole und deren verwendung zum schutz von pflanzen gegen befall durch mikroorganismen
EP0845460A4 (de) 1996-05-15 1998-09-02 Toray Industries VERFAHREN ZUR HERSTELLUNG VON 4a-ARYLDECAHYDROISOCHINOLIN-DERIVATEN
US5939551A (en) 1996-05-15 1999-08-17 Toray Industries, Inc. Process for producing 4a-aryldecahydroisoquinoline derivatives
FR2750427B1 (fr) * 1996-06-28 1998-08-07 Synthelabo Derives de 1-oxo-1, 2-dihydroisoquinoleine-4-propanamide, leur preparation et leur application en therapeutique
US5743070A (en) * 1996-08-16 1998-04-28 Automated Packaging Systems, Inc. Packaging machine, material and method
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
EP1019059A4 (de) 1997-01-24 2004-01-14 Univ California Verwendung von fxr, ppar-alpha- und lxr-alpha-aktivatoren zur wiederherstellung der barrierefunktion, zur förderung der epidermisdifferenzierung, und zur proliferationshemmung
EP0999208A4 (de) * 1997-05-30 2001-08-08 Meiji Seika Kaisha Stickstoffhaltige heterozyklische verbindungen und heilmittel zu behandlung von hyperlipämie die diese enthalten
FR2772760B1 (fr) * 1997-12-22 2000-02-04 Synthelabo Derives de 3-oxazol-5-yl-1-oxo-1,2-dihydroisoquinoleine-4- propanamide, leur preparation et leur application en therapeutique
AU5994199A (en) 1998-09-23 2000-04-10 Alexander Mata De Urquiza Analysis of ligand activated nuclear receptors (in vivo)
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
ATE274921T1 (de) 1999-03-26 2004-09-15 Hope City Verfahren zur selektion von fxr- rezeptormodulatoren
JP2002543216A (ja) 1999-04-30 2002-12-17 アーチ ディベロップメント コーポレイション ステロイド誘導体
EP1190065A2 (de) 1999-06-18 2002-03-27 Cv Therapeutics, Inc. Atp binding cassette transporter protein abc1 polypeptide
AU1291901A (en) 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
AU2000235960A1 (en) 2000-02-14 2001-08-27 Tularik, Inc. Lxr modulators
US6673543B2 (en) 2000-04-05 2004-01-06 Tularik, Inc. Solid phase synthesis of LXR ligands
AU2001262984A1 (en) 2000-05-03 2001-11-12 Tularik, Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
BR0206831A (pt) 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
DE60336901D1 (de) * 2002-03-07 2011-06-09 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren

Also Published As

Publication number Publication date
EP1572660B1 (de) 2011-01-26
AU2003301020A8 (en) 2004-07-22
WO2004058717A1 (en) 2004-07-15
TW200418801A (en) 2004-10-01
ES2361924T3 (es) 2011-06-24
US20040204447A1 (en) 2004-10-14
US20080132521A1 (en) 2008-06-05
EP1572660A1 (de) 2005-09-14
DE60335911D1 (de) 2011-03-10
AU2003301020A1 (en) 2004-07-22
WO2004058717A8 (en) 2004-08-19
US7265131B2 (en) 2007-09-04

Similar Documents

Publication Publication Date Title
DE60335911D1 (de) Isochinolinonderivate und deren verwendung als medikamente
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
ATE547416T1 (de) Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
DE60221969D1 (de) Durch piperidine-enthaltende gruppen substituierte chinoline und deren stickstoff-enthaltende derivate und ihre verwendung als antibakterielle wirkstoffe
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
MY137535A (en) New pyrrolidinium derivatives
DE502004006507D1 (de) Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
DE60118975D1 (de) Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE60124761D1 (de) Chinoline und deren in der 4-stellung durch eine piperazinhaltige gruppe substituierte nitrogenierte derivate und deren verwendung als antibakterielle mittel
ATE556056T1 (de) Pyridylderivate und deren verwendung als therapeutische mittel
DE69431069D1 (de) Cyclische amidderivate als neurokinin a antagonisten
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
DE60325493D1 (de) Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE495187T1 (de) Dalda-analoge und ihre verwendung
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
DE602004031410D1 (de) Inden derivate als pharmazeutika
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
DE69803383D1 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties